- Home
- IPHA vs MPAA Comparison
IPHA vs MPAA Comparison
Compare IPHA & MPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- MPAA
- Stock Information
- Founded
- IPHA 1999
- MPAA 1968
- Country
- IPHA France
- MPAA United States
- Employees
- IPHA N/A
- MPAA N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- MPAA Auto Parts:O.E.M.
- Sector
- IPHA Health Care
- MPAA Consumer Discretionary
- Exchange
- IPHA Nasdaq
- MPAA Nasdaq
- Market Cap
- IPHA 160.1M
- MPAA 188.9M
- IPO Year
- IPHA 2019
- MPAA 1994
- Fundamental
- Price
- IPHA $1.74
- MPAA $11.71
- Analyst Decision
- IPHA Strong Buy
- MPAA
- Analyst Count
- IPHA 1
- MPAA 0
- Target Price
- IPHA $11.00
- MPAA N/A
- AVG Volume (30 Days)
- IPHA 11.2K
- MPAA 297.8K
- Earning Date
- IPHA 09-11-2025
- MPAA 08-07-2025
- Dividend Yield
- IPHA N/A
- MPAA N/A
- EPS Growth
- IPHA N/A
- MPAA N/A
- EPS
- IPHA N/A
- MPAA N/A
- Revenue
- IPHA $20,831,349.00
- MPAA $757,354,000.00
- Revenue This Year
- IPHA $209.83
- MPAA $7.74
- Revenue Next Year
- IPHA $83.15
- MPAA $5.00
- P/E Ratio
- IPHA N/A
- MPAA N/A
- Revenue Growth
- IPHA N/A
- MPAA 5.53
- 52 Week Low
- IPHA $1.29
- MPAA $5.16
- 52 Week High
- IPHA $3.51
- MPAA $12.72
- Technical
- Relative Strength Index (RSI)
- IPHA 42.70
- MPAA 56.20
- Support Level
- IPHA $1.71
- MPAA $11.76
- Resistance Level
- IPHA $1.90
- MPAA $12.60
- Average True Range (ATR)
- IPHA 0.08
- MPAA 0.60
- MACD
- IPHA 0.00
- MPAA 0.10
- Stochastic Oscillator
- IPHA 47.62
- MPAA 71.75
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About MPAA Motorcar Parts of America Inc.
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard part in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.